Paul N. Moynagh

Paul N. Moynagh

Auto-generated profile, based on publicly available information

Paul N. Moynagh

Kathleen Lonsdale Institute for Human Health Research, Department of Biology, National University of Ireland Maynooth

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ECEoin Cummins
Eoin Cummins
EBEdurne Berra
Edurne Berra
KCKatrina M. Comerford
Katrina M. Comerford
AGAmandine Ginouves
Amandine Ginouves
KFKathleen T. Fitzgerald
Kathleen T. Fitzgerald
CTCormac Taylor
Cormac Taylor
Hypoxia is a feature of the microenvironment of a growing tumor. The transcription factor NFκB is activated in hypoxia, an event that has significant implications for tumor progression. Here, we demonstrate that hypoxia activates NFκB through a pathway involving activation of IκB kinase-β (IKKβ) leading to phosphorylation-dependent degradation of IκBα and liberation of NFκB. Furthermore, through increasing the pool and/or activation potential of IKKβ, hypoxia amplifies cellular sensitivity to stimulation with TNFα. Within its activation loop, IKKβ contains an evolutionarily conserved LxxLAP consensus motif for hydroxylation by prolyl hydroxylases (PHDs). Mimicking hypoxia by treatment of cells with siRNA against PHD-1 or PHD-2 or the pan-prolyl hydroxylase inhibitor DMOG results in NFκB activation. Conversely, overexpression of PHD-1 decreases cytokine-stimulated NFκB reporter activity, further suggesting a repressive role for PHD-1 in controlling the activity of NFκB. Hypoxia increases both the expression and activity of IKKβ, and site-directed mutagenesis of the proline residue (P191A) of the putative IKKβ hydroxylation site results in a loss of hypoxic inducibility. Thus, we hypothesize that hypoxia releases repression of NFκB activity through decreased PHD-dependent hydroxylation of IKKβ, an event that may contribute to tumor development and progression through amplification of tumorigenic signaling pathways.

13 March 2017 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
Yvonne DombrowskiYvonne Dombrowski
Yvonne Dombrowski
TOThomas O'Hagan
Thomas O'Hagan
MDMarie Dittmer
Marie Dittmer
RPRosana Penalva
Rosana Penalva
SMSonia R Mayoral
Sonia R Mayoral
DFDenise Fitzgerald
Denise Fitzgerald
Regeneration of myelin is a dynamic, yet enigmatic process. Dombrowski et al. uncover a central role for regulatory T (Treg) cells in driving oligodendrocyte differentiation, in part via CCN3, a novel factor in Treg function and oligodendrocyte biology. This identifies Treg cells as key cellular players in efficient remyelination. Regeneration of CNS myelin involves differentiation of oligodendrocytes from oligodendrocyte progenitor cells. In multiple sclerosis, remyelination can fail despite abundant oligodendrocyte progenitor cells, suggesting impairment of oligodendrocyte differentiation. T cells infiltrate the CNS in multiple sclerosis, yet little is known about T cell functions in remyelination. We report that regulatory T cells (Treg) promote oligodendrocyte differentiation and (re)myelination. Treg-deficient mice exhibited substantially impaired remyelination and oligodendrocyte differentiation, which was rescued by adoptive transfer of Treg. In brain slice cultures, Treg accelerated developmental myelination and remyelination, even in the absence of overt inflammation. Treg directly promoted oligodendrocyte progenitor cell differentiation and myelination in vitro. We identified CCN3 as a Treg-derived mediator of oligodendrocyte differentiation and myelination in vitro. These findings reveal a new regenerative function of Treg in the CNS, distinct from immunomodulation. Although the cells were originally named 'Treg' to reflect immunoregulatory roles, this also captures emerging, regenerative Treg functions.

10 September 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MCMichael Carty
Michael Carty
RGRory Goodbody
Rory Goodbody
MSMartina Schröder
Martina Schröder
JSJulianne Stack
Julianne Stack
PMPaul N Moynagh
Paul N Moynagh
ABAndrew Bowie
Andrew Bowie

15 October 2005 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
PMPaul N. Moynagh
Paul N. Moynagh
The nuclear factor (NF)-κB transcription factor regulates expression of numerous components of the immune system (Li and Verma, 2002). These include proinflammatory cytokines, chemokines, adhesion molecules and inducible enzymes such as cycloxygenase-2 and inducible nitric oxide synthase, which regulate the innate immune response, as well as proteins that regulate the specific immune response, such as major histocompatibility complex and co-stimulatory molecules crucial to the induction phase of specific immunity, and cytokines like interleukin (IL)-2, IL-12 and interferon-γ that control lymphocyte proliferation and differentiation. Dysregulation of this transcription factor can thus lead to inflammatory and autoimmune diseases (Yamamoto and Gaynor, 2001). Since NF-κB also regulates the expression of a variety of proteins that inhibit apoptosis and promote cell survival/proliferation, it is also implicated in carcinogenesis (Karin et al., 2002)

1 September 2005 in Trends in Immunology
Verified
Journal Article
Closed access
PMPaul N. Moynagh
Paul N. Moynagh

22 August 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
FHF Humphries
F Humphries
SYS Yang
S Yang
BWB Wang
B Wang
PMP N Moynagh
P N Moynagh